-
Biologics: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Recombinant follitropin alfa/lutropin alfa in fertility treatment
Review
(3593) Views (818) Full article downloads
Authors: Ahmed Gibreel, Siladitya Bhattacharya
Published Date December 2009
Volume 2010:4 Pages 5 - 17
DOI: http://dx.doi.org/10.2147/BTT.S3326
Ahmed Gibreel1, Siladitya Bhattacharya2
1School of Medicine and Dentistry, University of Aberdeen; 2Aberdeen Maternity Hospital, Aberdeen, UK
Abstract: Recombinant human follicle stimulating hormone (rFSH) and luteinizing hormone (LH), also known as follitropin alpha and lutropin alpha, are manufactured by genetic engineering techniques which ensure high quality and batch to batch consistency. Follitropin alpha can be used for controlled ovarian hyperstimulation in assisted reproduction, ovulation induction for WHO group I and II anovulatory infertility and in men with hypogonadotrophic hypogonadism (HH) or idiopathic oligo-asthenospermia. Current evidence suggests superiority of urinary human menopausal gonadotropin (HMG) over follitropin alpha in controlled ovarian hyperstimulation for IVF in terms of live birth rate per couple. Addition of lutropin to follitropin alpha in an unselected IVF population does not appear to confer any benefit; however, it may have a role in ovulation induction in women with hypothalamic hypogonadism. Urinary HMG preparations (especially currently available highly purified preparations) are more cost effective than rFSH in terms of cost per ongoing pregnancy. However, women using rFSH injection pen devices have higher levels of satisfaction as compared to those using urinary HMG by means of conventional syringes.
Keywords: infertility, follicle stimulating hormone, luteinizing hormone, follitropin alpha, lutropin alpha, in-vitro fertilization, urinary gonadotrophins
Readers of this article also read:
Challenges in the management of juvenile idiopathic arthritis with etanercept
Review of the safety, efficacy, costs and patient acceptability of recombinant follicle-stimulating hormone for injection in assisting ovulation induction in infertile women
Safety of etanercept in elderly subjects with rheumatoid arthritis
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model
Management of patients with advanced non-small cell lung cancer: role of gefitinib
Palliative treatment of malignant ascites: profile of catumaxomab
Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Journal Indexing
See where all the Dove Press journals are indexed
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




